Search

Your search keyword '"Borer, Jeffrey S."' showing total 468 results
Start Over Author "Borer, Jeffrey S." Search Limiters Full Text
468 results on '"Borer, Jeffrey S."'

6. Medical Misinformation: Vet the Message!

Author

Hill, Joseph A., Agewall, Stefan, Baranchuk, Adrian, Booz, George W., Borer, Jeffrey S., Camici, Paolo G., Chen, Peng-Sheng, Dominiczak, Anna F., Erol, Çetin, Grines, Cindy L., Gropler, Robert, Guzik, Tomasz J., Heinemann, Markus K., Iskandrian, Ami E., Knight, Bradley P., London, Barry, Lüscher, Thomas F., Metra, Marco, Musunuru, Kiran, Nallamothu, Brahmajee K., Natale, Andrea, Saksena, Sanjeev, Picard, Michael H., Rao, Sunil V., Remme, Willem J., Rosenson, Robert S., Sweitzer, Nancy K., Timmis, Adam, and Vrints, Christiaan

Published
2019
Full Text
View/download PDF

7. Efficacy of ivabradine in heart failure patients with a high‐risk profile (analysis from the SHIFT trial).

Author

Abdin, Amr, Komajda, Michel, Borer, Jeffrey S., Ford, Ian, Tavazzi, Luigi, Batailler, Cécile, Swedberg, Karl, Rosano, Giuseppe M.C., Mahfoud, Felix, and Böhm, Michael

Subjects
HEART failure patients, IVABRADINE, SYSTOLIC blood pressure, VENTRICULAR ejection fraction, HEART beat
Abstract

Aims: Early start and patient profile‐oriented heart failure (HF) management has been recommended. In this post hoc analysis from the SHIFT trial, we analysed the treatment effects of ivabradine in HF patients with systolic blood pressure (SBP) < 110 mmHg, resting heart rate (RHR) ≥ 75 b.p.m., left ventricular ejection fraction (LVEF) ≤ 25%, New York Heart Association (NYHA) Class III/IV, and their combination. Methods and results: The SHIFT trial enrolled 6505 patients (LVEF ≤ 35% and RHR ≥ 70 b.p.m.), randomized to ivabradine or placebo on the background of guideline‐defined standard care. Compared with placebo, ivabradine was associated with a similar relative risk reduction of the primary endpoint (cardiovascular death or HF hospitalization) in patients with SBP < 110 and ≥110 mmHg [hazard ratio (HR) 0.89, 95% confidence interval (CI) 0.74–1.08 vs. HR 0.80, 95% CI 0.72–0.89, P interaction = 0.34], LVEF ≤ 25% and >25% (HR 0.85, 95% CI 0.72–1.01 vs. HR 0.80, 95% CI 0.71–0.90, P interaction = 0.53), and NYHA III–IV and II (HR 0.83, 95% CI 0.74–0.94 vs. HR 0.81, 95% CI 0.69–0.94, P interaction = 0.79). The effect was more pronounced in patients with RHR ≥ 75 compared with <75 (HR 0.76, 95% CI 0.68–0.85 vs. HR 0.97, 95% CI 0.81–0.1.16, P interaction = 0.02). When combining these profiling parameters, treatment with ivabradine was also associated with risk reductions comparable with patients with low‐risk profiles for the primary endpoint (relative risk reduction 29%), cardiovascular death (11%), HF death (49%), and HF hospitalization (38%; all P values for interaction: 0.40). No safety concerns were observed between study groups. Conclusions: Our analysis shows that RHR reduction with ivabradine is effective and improves clinical outcomes in HF patients across various risk indicators such as low SBP, high RHR, low LVEF, and high NYHA class to a similar extent and without safety concern. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

10. Abstract 18347: Prognostic Significance of Activation Delay by Cross Correlation Analysis Using Tissue Doppler Imaging in Patients With Heart Failure and Narrow QRS Duration; an Echocardiography Guided Cardiac Resynchronization Therapy (Echo-CRT) Trial Substudy of Patients Not Randomized to CRT

Author

Tayal, Bhupendar, Gorcsan 3rd, John, Bax, Jeroen, Risum, Niels, Olsen, Niels Thue, Singh, Jagmeet P, Abraham, William T, Borer, Jeffrey S, Dickstein, Kenneth, Gras, Daniel, Krum, Henry, Brugada, Josep, Robertson, Michele, Ford, Ian, Holzmeister, Johannes, Ruschitzka, Frank, and Sogaard, Peter

Published
2017

17. Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: A consensus document from the mitral valve academic research consortium

Author

Stone, Gregg W., Vahanian, Alec S., Adams, David H., Abraham, William T., Borer, Jeffrey S., Bax, Jeroen J., Schofer, Joachim, Cutlip, Donald E., Krucoff, Mitchell W., Blackstone, Eugene H., Généreux, Philippe, Mack, Michael J., Siegel, Robert J., Grayburn, Paul A., Enriquez-Sarano, Maurice, Lancellotti, Patrizio, Filippatos, Gerasimos, and Kappetein, Arie Pieter

Published
2015
Full Text
View/download PDF

19. Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.

Author

Saag, Kenneth G., Becker, Michael A., White, William B., Whelton, Andrew, Borer, Jeffrey S., Gorelick, Philip B., Hunt, Barbara, Castillo, Majin, Gunawardhana, Lhanoo, Lloyd, Eric, Wigfield, Simon, Gwynne, Lauren, and Johnson, Danielle

Subjects
CARDIOVASCULAR disease related mortality, CAUSES of death, DRUG efficacy, RESEARCH, GOUT suppressants, ALLOPURINOL, CARDIOVASCULAR diseases, DESCRIPTIVE statistics, URIC acid, STATISTICAL sampling, GOUT, SECONDARY analysis, SYMPTOMS, DISEASE complications
Abstract

Objective: To investigate whether serum urate levels, number of gout flares, and tophi burden are related to death from cardiovascular (CV) causes after treatment with febuxostat or allopurinol in patients with gout from the Cardiovascular Safety of Febuxostat or Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES) trial. Methods: Patients were randomly assigned to receive febuxostat (40 mg or 80 mg once daily, according to serum urate levels at week 2) or allopurinol titrated in 100‐mg increments from 200–400 mg or 300–600 mg (with dose determined according to kidney function). Changes from baseline in serum urate level, gout flares, and tophus resolution were key exploratory efficacy parameters in the overall population and in subgroups of patients who died and those who did not die from a CV‐related cause. The latter subgroup included patients who died due to non‐CV causes and those who did not die due to any cause. Results: Patients received treatment with febuxostat (n = 3,098) or allopurinol (n = 3,092) for a median follow‐up period of 32 months (for a maximum of 85 months). In the overall population, mean serum urate levels were lower in those receiving febuxostat compared with those receiving allopurinol at most study visits. There were no associations between serum urate levels and death from CV causes with febuxostat. The number of gout flares requiring treatment was higher within 1 year of treatment with febuxostat compared with allopurinol (mean incidence of gout flares per patient‐years of exposure 1.33 versus 1.20), but was comparable thereafter and decreased overall throughout the study period (mean incidence of gout flares per patient‐years of exposure 0.35 versus 0.34 after 1 year of treatment; overall mean incidence 0.68 versus 0.63) irrespective of whether the patient died from a CV‐related cause. Overall, 20.8% of patients had ≥1 tophus at baseline; tophus resolution rates were similar between treatment groups, with cumulative resolution rates of >50%. Conclusion: In the CARES trial, febuxostat and allopurinol (≤600 mg doses) had comparable efficacy in patients with gout and CV disease, and there was no evidence of a relationship between death from CV causes and serum urate levels, number of gout flares, or tophus resolution among the patients receiving febuxostat. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

21. Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties

Author

Dobre, Daniela, Borer, Jeffrey S., Fox, Kim, Swedberg, Karl, Adams, Kirkwood F., Cleland, John G.F., Cohen-Solal, Alain, Gheorghiade, Mihai, Gueyffier, Francois, OʼConnor, Christopher M., Fiuzat, Mona, Patak, Athul, Piña, Ileana L., Rosano, Giuseppe, Sabbah, Hani N., Tavazzi, Luigi, and Zannad, Faiez

Published
2014
Full Text
View/download PDF

33. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study

Author

Krum, Henry, Massie, Barry, Abraham, William T., Dickstein, Kenneth, Kober, Lars, McMurray, John J.V., Desai, Ashkay, Gimpelewicz, Claudio, Kandra, Albert, Reimund, Bernard, Rattunde, Henning, Armbrecht, Juergen, Krum, H., Massie, B., Abraham, W., Dickstein, K., Kober, L., McMurray, J., Swedberg, Karl, Pocock, Stuart, Pitt, Bertram, Borer Jeffrey, S., Rouleau, Jean, Wibberg, Martina, Solomon, Scott, Desai Akshay, S., Finn, Peter, Weinrauch, Larry, Hartley, Howard, Pouleur, Anne-Catherine, Barkoudah, Ebrahim, Duong, Chau, and Rogers, Austin

Published
2011
Full Text
View/download PDF

34. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT)

Author

Gheorghiade, Mihai, Albaghdadi, Mazen, Zannad, Faiez, Fonarow, Gregg C., Böhm, Michael, Gimpelewicz, Claudio, Botha, Jaco, Moores, Shelley, Lewis, Eldrin F., Rattunde, Henning, Maggioni, Aldo, Gheorghiade, Mihai, Maggioni, Aldo, Fonarow, Gregg C., Böhm, Michael, Zannad, Faiez, Solomon, Scott, Lewis, Eldrin, Finn, Peter, Hartley, Howard, Weinrach, Larry, Barkoudah, Ebrahim, Duong, Chau, Rogers, Austin, Swedberg, Karl, Pocock, Stuart, Pitt, Bertram, Borer, Jeffrey S., Rouleau, Jean, and Wibberg, Martina

Published
2011
Full Text
View/download PDF

35. Reduced left ventricular contractility, increased diastolic operant stiffness and high energetic expenditure in patients with severe aortic regurgitation without indication for surgery

Author

Reil, Jan-Christian, primary, Reil, Gert-Hinrich, additional, Hecker, Nora, additional, Sequeira, Vasco, additional, Borer, Jeffrey S., additional, Stierle, Ulrich, additional, Lavall, Daniel, additional, Marquetand, Christoph, additional, Busch, Claudia, additional, Patzelt, Johannes, additional, Heringlake, Matthias, additional, Schäfers, Hans-Joachim, additional, Sievers, Hans-Hinrich, additional, Ensminger, Stephan, additional, and Aboud, Anas, additional

Published
2020
Full Text
View/download PDF

37. Relationship of Body Mass Index With Outcomes After Transcatheter Aortic Valve Replacement: Results From the National Cardiovascular Data–STS/ACC TVT Registry

Author

Sharma, Abhishek, primary, Lavie, Carl J., additional, Elmariah, Sammy, additional, Borer, Jeffrey S., additional, Sharma, Samin K., additional, Vemulapalli, Sreekanth, additional, Yerokun, Babatunde A., additional, Li, Zhuokai, additional, Matsouaka, Roland A., additional, and Marmur, Jonathan D., additional

Published
2020
Full Text
View/download PDF

43. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis

Author

Komajda, Michel, Böhm, Michael, Borer, Jeffrey S., Ford, Ian, Tavazzi, Luigi, Pannaux, Matthieu, and Swedberg, Karl

Subjects
R1
Abstract

Aims:\ud \ud A network meta‐analysis (NMA) of all recommended drug groups for the treatment of heart failure with reduced ejection fraction (HFrEF), including their combinations, was performed to assess the relative efficacy and incremental benefit.\ud Methods and results:\ud \ud A search was made in biomedical databases for randomized controlled trials published between 1987 and 2017 on angiotensin‐converting enzyme inhibitors (ACEIs), beta‐blockers (BBs), angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), ivabradine (IVA), or angiotensin receptor–neprilysin inhibitors (ARNI). A total of 58 relevant trials were identified. The relative efficacy of each treatment group (or combination) in terms of all‐cause mortality, cardiovascular mortality, all‐cause hospitalizations and hospitalizations for heart failure, per patient‐year of follow‐up, were combined in a random‐effects Bayesian NMA. The pairwise comparison between each regimen and for each outcome was estimated. The NMA was dominated by 15 large‐scale trials with between 1984 and 18 898 patient‐years of follow‐up. Combinations of drug groups showed incremental benefits on outcomes over single groups. The most effective combinations were ARNI+BB + MRA and ACEI+BB + MRA + IVA, showing reductions in all‐cause mortality (vs. placebo) of 62% and 59%, respectively; hazard ratios were 0.38 [credible interval (CrI) 0.20–0.65] and 0.41 (CrI 0.21–0.70); and in all‐cause hospitalizations with reductions of 42% for both. These two combinations were also the most effective for the other outcomes studied.\ud Conclusion:\ud \ud Our analysis shows that the incremental use of combinations of disease‐modifying therapies has resulted in the progressive improvement in mortality and hospitalization outcomes in HFrEF. Our findings support the current guideline recommendations.

Published
2018

44. Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen

Author

Reed, Grant W, Abdallah, Mouin S, Shao, Mingyuan, Wolski, Kathy, Wisniewski, Lisa, Yeomans, Neville, Lüscher, Thomas F, Borer, Jeffrey S, Graham, David Y, Husni, M Elaine, Solomon, Daniel H, Libby, Peter, Menon, Venu, Lincoff, A Michael, Nissen, Steven E, University of Zurich, and Nissen, Steven E

Subjects
11459 Center for Molecular Cardiology, 610 Medicine & health, 2705 Cardiology and Cardiovascular Medicine
Published
2018

47. Medical Misinformation

Author

Hill, Joseph A., primary, Agewall, Stefan, additional, Baranchuk, Adrian, additional, Booz, George W., additional, Borer, Jeffrey S., additional, Camici, Paolo G., additional, Chen, Peng-Sheng, additional, Dominiczak, Anna F., additional, Erol, Çetin, additional, Grines, Cindy L., additional, Gropler, Robert, additional, Guzik, Tomasz J., additional, Heinemann, Markus K., additional, Iskandrian, Ami E., additional, Knight, Bradley P., additional, London, Barry, additional, Lüscher, Thomas F., additional, Metra, Marco, additional, Musunuru, Kiran, additional, Nallamothu, Brahmajee K., additional, Natale, Andrea, additional, Saksena, Sanjeev, additional, Picard, Michael H., additional, Rao, Sunil V., additional, Remme, Willem J., additional, Rosenson, Robert S., additional, Sweitzer, Nancy K., additional, Timmis, Adam, additional, and Vrints, Christiaan, additional

Published
2019
Full Text
View/download PDF

48. Medical misinformation: vet the message!

Author

Hill, Joseph A, primary, Agewall, Stefan, additional, Baranchuk, Adrian, additional, Booz, George W, additional, Borer, Jeffrey S, additional, Camici, Paolo G, additional, Chen, Peng-Sheng, additional, Dominiczak, Anna F, additional, Erol, Çetin, additional, Grines, Cindy L, additional, Gropler, Robert, additional, Guzik, Tomasz J, additional, Heinemann, Markus K, additional, Iskandrian, Ami E, additional, Knight, Bradley P, additional, London, Barry, additional, Lüscher, Thomas F, additional, Metra, Marco, additional, Musunuru, Kiran, additional, Nallamothu, Brahmajee K, additional, Natale, Andrea, additional, Saksena, Sanjeev, additional, Picard, Michael H, additional, Rao, Sunil V, additional, Remme, Willem J, additional, Rosenson, Robert S, additional, Sweitzer, Nancy K, additional, Timmis, Adam, additional, and Vrints, Christiaan, additional

Published
2019
Full Text
View/download PDF

49. Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial

Author

Varma, Niraj, Sogaard, Peter, Bax, Jeroen J, Abraham, William T, Borer, Jeffrey S, Dickstein, Kenneth, Singh, Jagmeet P, Gras, Daniel, Holzmeister, Johannes, Brugada, Josep, Ruschitzka, Frank, Varma, Niraj, Sogaard, Peter, Bax, Jeroen J, Abraham, William T, Borer, Jeffrey S, Dickstein, Kenneth, Singh, Jagmeet P, Gras, Daniel, Holzmeister, Johannes, Brugada, Josep, and Ruschitzka, Frank

Abstract

BACKGROUND Longer QRS duration (QRSd) improves, but increased left ventricular (LV) end-diastolic volume (LVEDV) reduces, efficacy of cardiac resynchronization therapy (CRT). QRSd/LVEDV ratios differ between sexes. We hypothesized that in the EchoCRT (Echocardiography Guided Cardiac Resynchronization Therapy) trial enrolling patients with heart failure with QRSd <130 ms, those with larger LVEDV would deteriorate but those with the highest QRSd/LVEDV would with CRT. METHODS AND RESULTS Primary outcome in patients (n=787, 72% men, 93% New York Heart Association class III, QRSd <130 ms, LV ejection fraction ≤35%, LV dilation and dyssynchrony) randomized to CRT-ON or CRT-OFF and followed up for 19 months was compared according to LVEDV (height indexed) or QRSd/LVEDV ratio, in multivariable analysis. Structural remodeling was assessed echocardiographically 6 months after implantation. Patients with baseline LVEDV higher than or equal to median worsened with CRT (death/heart failure hospitalization: CRT-ON versus CRT-OFF, 35.2% versus 24.5% [hazard ratio, 1.64; 95% confidence interval, 1.11-2.42; =0.012]), but those with LVEDV lower than median remained unaffected. Patients with the highest QRSd/LVEDV ratio improved with CRT (death/heart failure hospitalization in top quartile: 20.9% in CRT-ON [n=91] versus 28.3% in CRT-OFF [n=106] [hazard ratio, 0.64; 95% confidence interval, 0.34-1.24; =0.188], versus the remaining quartiles: 31.7% in CRT-ON [n=300] versus 24.8% in CRT-OFF [n=290] [hazard ratio, 1.47; 95% confidence interval, 1.07-2.02; =0.016], test for interaction =0.046). QRSd and dyssynchrony were similar between groups. The 3-way test for interaction indicated no sex-specific effects. However, numerically, men with LVEDV higher than or equal to median accounted for worse outcomes of CRT-ON. Women, with the highest QRSd/LVEDV ratio exhibited significant reverse remodeling. CONCLUSION CRT has opposite effects among patients with heart failure with QRSd <130 ms accord

Published
2018

50. Reduced left ventricular contractility, increased diastolic operant stiffness and high energetic expenditure in patients with severe aortic regurgitation without indication for surgery.

Author

Reil, Jan-Christian, Reil, Gert-Hinrich, Hecker, Nora, Sequeira, Vasco, Borer, Jeffrey S., Stierle, Ulrich, Lavall, Daniel, Marquetand, Christoph, Busch, Claudia, Patzelt, Johannes, Heringlake, Matthias, Schäfers, Hans-Joachim, Sievers, Hans-Hinrich, Ensminger, Stephan, and Aboud, Anas

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results